Waltham, Massachusetts 02453
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance • Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic
• Closed BioLife acquisition, which fast-tracks Repligen’s leadership and offering in high-growth cell therapy market
• Raising FY26 revenue guidance to $844-$852 million which represents reported revenue growth of 14.5% - 15.5%
-- Repligen Corporation (NASDAQ:RGEN), today reported financial results for its third quarter of 2026, covering the three-month period ended September 30, 2026. The Company is also providing updated financial guidance for the full year 2026.
Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End- market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book.”
Mr. Loeillot continued, “The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Early customer feedback has been very encouraging, and we have already taken actions to realize a sizable portion of our expected operating expense synergies. Our strong year-to-date performance, continued order momentum and the addition of BioLife give us confidence to raise our full-year guidance again.”
The acquisition strengthens Repligen's position in cell therapy by adding a differentiated, deeply embedded consumables platform with recurring revenue, commercial-stage exposure, and strong customer workflow integration. The combination expands Repligen's portfolio and is expected to enhance the Company's long-term growth, margin profile, and earnings power.
• New Repligen Training & Innovation Center (“RTIC”). On October 23, 2026, opened a new RTIC in Seoul, South Korea. This underscores Repligen’s commitment to a strategically important market that has become one of the world’s leading hubs for biologics and CDMO manufacturing.
All adjusted figures are non-GAAP and, except for earnings per share (“EPS”), are rounded to the nearest million, and are reconciled in the tables included later in this press release.
• Q3 reported revenue was $209.3 million, compared to $188.8 million, an increase of 11% as reported and 12.5% organic.
Q3 loss from operations was $29.5 million primarily driven by intangible asset impairment charge, compared to income from operations of $16.8 million. Q3 loss per share was $0.68 on a fully diluted basis, compared to EPS of $0.26.
Q3 adjusted income from operations was $33.3 million, compared to $26.8 million.
Cash, cash equivalents and marketable securities at September 30, 2026, were $863 million, compared to $768 million at December 31, 2025.
Our financial guidance for the full year 2026 includes the expected impact of BioLife Solutions from the closing date of October 6, 2026. Our Adjusted (non- GAAP) guidance excludes the impact of any other potential business acquisitions and future fluctuations in foreign currency exchange rates.
Total reported revenue guidance reflects a neutral impact from foreign currency and an approximately 2.5 point tailwind from inorganic growth primarily from the BioLife acquisition net of the divestiture of Polymem .
Repligen will host a conference call and webcast today, October 27, 2026, at 8:00 a.m. ET, to discuss third quarter 2026 financial results, corporate developments and financial guidance for 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 877042431. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of the Company’s website. 2
Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies and integrated solutions that support critical steps in the manufacturing and delivery of biologic drugs that improve human health worldwide. As a trusted partner to biopharmaceutical developers and manufacturers and CDMOs worldwide, we help improve productivity, simplify complex workflows, and advance the next generation of biologic therapies. Repligen technologies support the production of a broad range of biologic modalities, helping customers navigate evolving manufacturing challenges from process development through commercial production. Our global team combines deep scientific expertise, innovation, and a customer-focused mindset “inspiring advances in bioprocessing” to help solve complex challenges across biologics manufacturing. For more information, please visit our website at www.repligen.com, and follow us on LinkedIn.
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (“GAAP”), the following Adjusted (“non- GAAP”) measures of financial performance are included in this release: organic revenue and organic revenue growth; adjusted gross profit and adjusted gross margin; adjusted income from operations and adjusted operating margin; organic adjusted operating margin year-over-year change; adjusted net income and adjusted net income margin; adjusted earnings per share (diluted); adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA margin. The Company provides the impact of foreign currency translation, to enable determination of revenue and margin growth rates at constant currency. To calculate the impact of foreign currency translation, the Company converts the reported amounts from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior year periods.
The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition, integration and divestiture costs; restructuring charges including the costs of severance and accelerated depreciation among other non- cash charges; inventory step-up costs and adjustments; transformation costs including incremental, non-recurring expenses for discrete strategic projects that are designed to deliver long-term benefits, including improvements to enhance productivity and enable company growth that do not meet the definition of restructuring; contingent consideration related to the Company’s acquisitions; intangible amortization costs; intangible asset impairment charges; non-cash interest expense related to the accretion of the debt discount; amortization of debt issuance costs related to Company’s convertible debt; foreign currency impact of certain intercompany loans; loss on sale of business; and, the related impact on tax of non-GAAP charges.
These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded. Additionally, for a project to be considered transformational, the project expenses are expected to bring long-term growth, profitability improvements and defined process and technology improvements. Our transformation initiative is multi-year but each project has a discrete, defined timeline. Further, organic adjusted operating margin year- over-year change excludes the effect of adjustments above, as well as the impact of mergers, acquisitions and divestitures and foreign exchange. This measure is used by the Company in periods of acquisition because the timing, size and number of such transactions and their related impact on the financial statements may vary and make comparison of long-term results difficult.
All reconciliations of above GAAP figures to adjusted (non-GAAP) figures are detailed in the tables included later in this press release. Certain prior year amounts have been reclassified to conform with the current year presentation. When analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.
The Company does not provide GAAP financial measures on a forward-looking basis as the Company is unable to provide a quantitative reconciliation of forward- looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. The Company cannot reasonably predict items including, but not limited to, the timing and amount of future restructuring and cost-savings actions or transformation, acquisition and integration related costs. These items are generally uncertain and are not indicative of ongoing operations of the business, and the impact could be material to our results in accordance with GAAP. 3
This press release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein which do not describe historical facts, including, among others, any express or implied statements or guidance regarding current or future financial performance and position, including our 2026 financial guidance and related assumptions; expected demand in the markets in which we operate; and the expected performance of our business and momentum across our portfolio, are based on management’s current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds; the risk that we have assumed that markets and franchises will improve and grow as predicted; our ability to achieve our 2026 financial guidance; our ability to develop and commercialize products and the market acceptance of our products; our ability to successfully integrate BioLife, including its operations, products, systems and personnel, in a timely manner or at all, and to realize the expected benefits and synergies of the acquisition; the future performance of BioLife and the combined company, including the impact of the acquisition on our financial results and outlook; the risk of unanticipated costs, liabilities or disruptions to our or BioLife's business, customer, supplier or employee relationships resulting from the acquisition; our ability to successfully integrate any other acquired businesses and relevant personnel in a timely manner or at all, and to achieve the expected benefits of such acquisitions; the risk that demand for our products could decline, which could adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing companies; risks around the Company’s effectiveness of disclosure controls and procedures and the effectiveness of our internal control over financial reporting; our compliance with all U.S. Food and Drug Administration and European Medicines Evaluation Agency regulations; our volatile stock price; the impact of tariffs on our business, and other risks and uncertainties detailed in Repligen’s filings with the U.S. Securities and Exchange Commission (the Commission), including our Annual Report on Form 10-K for the year ended December 31, 2025 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any subsequent filings made with the Commission, which are available at the Commission’s website at www.sec.gov. Actual results may differ materially from those Repligen contemplated by these forward-looking statements, which reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Repligen disclaims any obligation to update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward- looking statements.
September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash and cash equivalents $ 726,960 $ 566,021 Marketable securities 136,019 201,607 Accounts receivable, net of allowances of $3,273 and $2,767 at September 30, 151,235 158,587 2026, and December 31, 2025, respectively Inventories, net 182,205 170,458 Prepaid expenses and other current 45,565 40,712 assets Total current assets 1,241,984 1,137,385 Property, plant and equipment, net 163,561 186,614 Intangible assets, net 305,291 386,147 Goodwill 1,100,319 1,114,408 Deferred tax assets 716 694 Operating lease right of use assets 112,472 119,538 Other noncurrent assets 2,065 4,913 Total assets $ 2,926,408 $ 2,949,699 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 27,697 $ 30,010 Operating lease liabilities 20,397 21,559 Contingent consideration 2,254 5,049 Accrued liabilities 75,338 79,208 Total current liabilities 125,686 135,826 Convertible Senior Notes due 2028, 555,596 542,213 net Deferred tax liabilities 19,909 22,496 Noncurrent operating lease 116,248 126,176 liabilities Noncurrent contingent consideration — 1,304 Other noncurrent liabilities 17,232 15,555 Total liabilities 834,671 843,570 Stockholders' equity: Preferred stock, $0.01 par value, 5,000,000 shares authorized, no — — shares issued or outstanding Common stock, $0.01 par value; 80,000,000 shares authorized; 56,692,755 shares at September 30, 2026, and 567 563 56,325,429 shares at December 31, 2025, issued and outstanding Additional paid-in capital 1,685,620 1,651,849 Accumulated other comprehensive loss -25,607 -2,531 Retained earnings 431,157 456,248 Total stockholders’ equity 2,091,737 2,106,129 Total liabilities and stockholders’ $ 2,926,408 $ 2,949,699 equity
Nine Months Ended Cash flows from September 30, operating activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net (loss) income $ -25,091 $ 35,607 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Depreciation and 57,948 58,794 amortization Intangible asset 41,242 — impairment charges Amortization of debt discount and 13,383 12,360 issuance costs Inventory step-up — 1,069 amortization Loss on sale of 13,694 — business Stock-based 25,690 24,621 compensation Deferred income taxes, -944 -5,784 net Change in fair value of contingent 1,459 -12,087 consideration Net unrealized foreign exchange loss -683 -12,443 (gain) Operating lease right of use asset 14,189 13,570 amortization Other adjustments and -1,754 2,532 non-cash items Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable 3,383 -7,302 Inventories -16,070 -5,346 Prepaid expenses and other current -3,732 -5,494 assets Other noncurrent 1,916 -1,727 assets Accounts payable -523 -5,083 Accrued liabilities -2,443 9,629 Operating lease -18,796 -12,096 liabilities Noncurrent liabilities 1,292 893 Total cash provided by operating 104,160 91,713 activities Cash flows from (for) investing activities Acquisitions, net of — -69,954 cash acquired Divestiture proceeds, net of cash 3,637 — divested Purchases of -200,499 — marketable securities Maturities and sales of marketable 271,073 — securities Additions to capitalized software -1,307 -2,055 costs Purchases of property, plant and -14,992 -15,366 equipment Sale of property, — 42 plant and equipment Other investing — -2,397 activities Total cash provided by (used in) 57,912 -89,730 investing activities Cash flows from (for) financing activities Proceeds from exercise 15,850 2,142 of stock options Payment of tax withholding obligation on -7,765 -7,994 vesting of restricted stock Payment of earnout -5,225 -9,548 consideration Total cash provided by (used in) 2,860 -15,400 financing activities Effect of exchange rate changes on cash, -1,943 4,809 cash equivalents and restricted cash Net increase (decrease) in cash, cash 162,989 -8,608 equivalents and restricted cash Cash, cash equivalents and restricted $ 566,021 $ 757,355 cash, beginning of period Cash, cash equivalents and restricted $ 729,010 $ 748,747 cash, end of period
(Unaudited, amounts in thousands, except percentage and earnings per share data)
Reconciliation of Total Revenue (GAAP) Growth to Organic Revenue Growth (Non- GAAP)
Reconciliation of (Loss) Income from Operations (GAAP) to Adjusted Income from Operations (Non-GAAP)
(1) Restructuring activities and other charges includes the costs of severance, lease impairment and accelerated depreciation among other non-cash charges. Charges for the three and nine months ended September 30, 2026, consists of activities to simplify the global manufacturing footprint of the organization and align its workforce to support long-term company growth.
(2) For the three and nine months ended September 30, 2026, transformation costs include $3.9 million and $8.8 million, respectively, of expenses for discrete strategic projects that are designed to deliver long-term growth under our Transformation Office, partially offset by $0.6 million and $2.5 million, respectively, for the benefit received from the sale of inventory that had previously been reserved for as part of past restructuring plans. The three and nine months ended September 30, 2025, includes a benefit of $1.0 million and $3.3 million, respectively, from the sale of inventory that had previously been reserved as part of past restructuring plans.
(3) During the three and nine months ended September 30, 2026, we recorded foreign currency (gains) and losses on certain intercompany loans of $(1.0) million and $0.5 million, respectively. This is recorded in other income (expense), net within the condensed consolidated statements of operations.
(4) Other charges for the three and nine months ended September 30, 2026, includes other expenses or (benefits) that are non-indicative of our ongoing performance. The three and nine months ended September 30, 2025 , includes charges related to one-time events relating to a cybersecurity incident, net of insurance, and costs associated with the restatement of previously issued financial statements.
(5) GAAP loss per share—diluted for the three and nine months ended September 30, 2026, excludes 328,882 and 313,150 potentially dilutive shares, respectively, as their inclusion would have been antidilutive due to the net loss for each period. Adjusted earnings per share—diluted for the same periods was calculated using 56,886,642 and 56,757,704 diluted shares, respectively. 10
Full text with the tables
Exhibit 99.1
Repligen Corporation
41 Seyon Street
Building #1, Suite 100
Waltham, Massachusetts 02453
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026
Financial Guidance
• Third quarter revenue of $209 million, a year-over-year increase of 11% as
reported and 12.5% organic
• Closed BioLife acquisition, which fast-tracks Repligen’s leadership and
offering in high-growth cell therapy market
• Raising FY26 revenue guidance to $844-$852 million which represents reported
revenue growth of 14.5% - 15.5%
WALTHAM, Mass., October 27, 2026
-- Repligen Corporation (NASDAQ:RGEN), today reported financial results for its
third quarter of 2026, covering the three-month period ended September 30, 2026.
The Company is also providing updated financial guidance for the full year 2026.
Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We
delivered a record third quarter, with $209 million in revenue and 12.5% organic
growth, driven by continued strength across our diversified portfolio. End-
market demand continues to improve, with healthy trends in consumables and
services complemented by a growing capital equipment order book.”
Mr. Loeillot continued, “The completion of the BioLife acquisition in October
marks a significant milestone for Repligen, and integration is progressing well.
Early customer feedback has been very encouraging, and we have already taken
actions to realize a sizable portion of our expected operating expense
synergies. Our strong year-to-date performance, continued order momentum and the
addition of BioLife give us confidence to raise our full-year guidance again.”
BUSINESS HIGHLIGHTS
•
Completed Acquisition of BioLife Solutions.
The acquisition strengthens Repligen's position in cell therapy by adding a
differentiated, deeply embedded consumables platform with recurring revenue,
commercial-stage exposure, and strong customer workflow integration. The
combination expands Repligen's portfolio and is expected to enhance the
Company's long-term growth, margin profile, and earnings power.
• New Repligen Training & Innovation Center (“RTIC”). On October 23, 2026,
opened a new RTIC in Seoul, South Korea. This underscores Repligen’s commitment
to a strategically important market that has become one of the world’s leading
hubs for biologics and CDMO manufacturing.
FINANCIAL PERFORMANCE
Q3 2026 Financial Performance (compared to prior year periods except as noted)
All adjusted figures are non-GAAP and, except for earnings per share (“EPS”),
are rounded to the nearest million, and are reconciled in the tables included
later in this press release.
• Q3 reported revenue was $209.3 million, compared to $188.8 million, an
increase of 11% as reported and 12.5% organic.
•
GAAP Results.
Q3 loss from operations was $29.5 million primarily driven by intangible asset
impairment charge, compared to income from operations of $16.8 million. Q3 loss
per share was $0.68 on a fully diluted basis, compared to EPS of $0.26.
•
Adjusted Results.
Q3 adjusted income from operations was $33.3 million, compared to $26.8 million.
Q3 adjusted EPS was $0.53 on a fully diluted basis, compared to $0.46.
1
MARGIN SUMMARY
GAAP Margins Q3 2026 Q3 2025 Q3-YTD 2026 Q3-YTD 2025
Gross Margin 53.0% 53.2% 54.2% 52.7%
Operating (Loss) EBIT (14.1)% 8.9% 0.1% 6.9%
Margin
Net (Loss) Income Margin (18.4)% 7.9% (4.1)% 6.6%
Adjusted (non-GAAP) Q3 2026 Q3 2025 Q3-YTD 2026 Q3-YTD 2025
Margins
Gross Margin 53.0% 53.3% 54.1% 52.7%
Operating (EBIT) Margin 15.9% 14.2% 16.0% 13.3%
Net Income Margin 14.3% 13.7% 14.4% 12.8%
EBITDA Margin 20.9% 19.0% 21.0% 18.7%
Cash, cash equivalents and marketable securities at September 30, 2026, were
$863 million, compared to $768 million at December 31, 2025.
FINANCIAL GUIDANCE FOR FULL YEAR 2026
All adjusted figures are non-GAAP.
Our financial guidance for the full year 2026 includes the expected impact of
BioLife Solutions from the closing date of October 6, 2026. Our Adjusted (non-
GAAP) guidance excludes the impact of any other potential business acquisitions
and future fluctuations in foreign currency exchange rates.
CURRENT GUIDANCE
(at October 27, 2026)
FY 2026 Adjusted (non-GAAP)
───────────────────────────────────────────────────────
Total Reported Revenue $844M - $852M
Reported Growth 14.5% - 15.5%
Organic Growth 12% - 13%
Gross Margin 53.7% - 54.2%
Income from Operations $135M - $139M
Operating Margin 16.0% - 16.3%
Other Income (Expense) ~$18M
Adjusted EBITDA Margin ~21%
Tax Rate on Pre-Tax Income ~22%
Net Income $119M - $122M
Earnings Per Share - Diluted $2.05 - $2.09
Total reported revenue guidance reflects a neutral impact from foreign currency
and an approximately 2.5 point tailwind from inorganic growth primarily from the
BioLife acquisition net of the divestiture of Polymem .
Conference Call and Webcast Access
Repligen will host a conference call and webcast today, October 27, 2026, at
8:00 a.m. ET, to discuss third quarter 2026 financial results, corporate
developments and financial guidance for 2026. The conference call will be
accessible by dialing toll-free (833) 461-5787 for domestic callers and (585)
542-9983 for international callers. The meeting ID is: 877042431. In addition, a
webcast will be accessible via the Investor Relations section of the Company’s
website. The webcast will be archived for a period of time following the live
event. You can access the replay on the Investor Relations section of the
Company’s website.
2
About Repligen Corporation
Repligen Corporation is a global bioprocessing company that develops and
commercializes innovative technologies and integrated solutions that support
critical steps in the manufacturing and delivery of biologic drugs that improve
human health worldwide. As a trusted partner to biopharmaceutical developers and
manufacturers and CDMOs worldwide, we help improve productivity, simplify
complex workflows, and advance the next generation of biologic therapies.
Repligen technologies support the production of a broad range of biologic
modalities, helping customers navigate evolving manufacturing challenges from
process development through commercial production. Our global team combines deep
scientific expertise, innovation, and a customer-focused mindset “inspiring
advances in bioprocessing” to help solve complex challenges across biologics
manufacturing. For more information, please visit our website at
www.repligen.com, and follow us on LinkedIn.
Non-GAAP Measures of Financial Performance
To supplement our financial statements, which are presented on the basis of U.S.
generally accepted accounting principles (“GAAP”), the following Adjusted (“non-
GAAP”) measures of financial performance are included in this release: organic
revenue and organic revenue growth; adjusted gross profit and adjusted gross
margin; adjusted income from operations and adjusted operating margin; organic
adjusted operating margin year-over-year change; adjusted net income and
adjusted net income margin; adjusted earnings per share (diluted); adjusted
earnings before interest, taxes, depreciation and amortization (EBITDA), and
adjusted EBITDA margin. The Company provides the impact of foreign currency
translation, to enable determination of revenue and margin growth rates at
constant currency. To calculate the impact of foreign currency translation, the
Company converts the reported amounts from local currency to U.S. dollars using
constant foreign currency exchange rates in the current and prior year periods.
The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the
impact of: acquisition, integration and divestiture costs; restructuring charges
including the costs of severance and accelerated depreciation among other non-
cash charges; inventory step-up costs and adjustments; transformation costs
including incremental, non-recurring expenses for discrete strategic projects
that are designed to deliver long-term benefits, including improvements to
enhance productivity and enable company growth that do not meet the definition
of restructuring; contingent consideration related to the Company’s
acquisitions; intangible amortization costs; intangible asset impairment
charges; non-cash interest expense related to the accretion of the debt
discount; amortization of debt issuance costs related to Company’s convertible
debt; foreign currency impact of certain intercompany loans; loss on sale of
business; and, the related impact on tax of non-GAAP charges.
These costs are excluded because management believes that such expenses do not
have a direct correlation to future business operations, nor do the resulting
charges recorded accurately reflect the performance of our ongoing operations
for the period in which such charges are recorded. Additionally, for a project
to be considered transformational, the project expenses are expected to bring
long-term growth, profitability improvements and defined process and technology
improvements. Our transformation initiative is multi-year but each project has a
discrete, defined timeline. Further, organic adjusted operating margin year-
over-year change excludes the effect of adjustments above, as well as the impact
of mergers, acquisitions and divestitures and foreign exchange. This measure is
used by the Company in periods of acquisition because the timing, size and
number of such transactions and their related impact on the financial statements
may vary and make comparison of long-term results difficult.
All reconciliations of above GAAP figures to adjusted (non-GAAP) figures are
detailed in the tables included later in this press release. Certain prior year
amounts have been reclassified to conform with the current year presentation.
When analyzing the Company’s operating performance and guidance, investors
should not consider non-GAAP measures as a substitute for the comparable
financial measures prepared in accordance with GAAP.
The Company does not provide GAAP financial measures on a forward-looking basis
as the Company is unable to provide a quantitative reconciliation of forward-
looking non-GAAP measures to the most directly comparable forward-looking GAAP
measure, without unreasonable effort. The Company cannot reasonably predict
items including, but not limited to, the timing and amount of future
restructuring and cost-savings actions or transformation, acquisition and
integration related costs. These items are generally uncertain and are not
indicative of ongoing operations of the business, and the impact could be
material to our results in accordance with GAAP.
3
Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant
to and in reliance upon the safe harbor provisions of federal securities laws,
including the Private Securities Litigation Reform Act of 1995, Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Any statements contained herein which do not
describe historical facts, including, among others, any express or implied
statements or guidance regarding current or future financial performance and
position, including our 2026 financial guidance and related assumptions;
expected demand in the markets in which we operate; and the expected performance
of our business and momentum across our portfolio, are based on management’s
current expectations and beliefs and are forward-looking statements which
involve risks and uncertainties that could cause actual results to differ
materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, our ability to successfully
grow our bioprocessing business; our ability to manage through and predict
headwinds; the risk that we have assumed that markets and franchises will
improve and grow as predicted; our ability to achieve our 2026 financial
guidance; our ability to develop and commercialize products and the market
acceptance of our products; our ability to successfully integrate BioLife,
including its operations, products, systems and personnel, in a timely manner or
at all, and to realize the expected benefits and synergies of the acquisition;
the future performance of BioLife and the combined company, including the impact
of the acquisition on our financial results and outlook; the risk of
unanticipated costs, liabilities or disruptions to our or BioLife's business,
customer, supplier or employee relationships resulting from the acquisition; our
ability to successfully integrate any other acquired businesses and relevant
personnel in a timely manner or at all, and to achieve the expected benefits of
such acquisitions; the risk that demand for our products could decline, which
could adversely impact our future revenues, cash flows, results of operations
and financial condition; our ability to compete with larger, better financed
bioprocessing companies; risks around the Company’s effectiveness of disclosure
controls and procedures and the effectiveness of our internal control over
financial reporting; our compliance with all U.S. Food and Drug Administration
and European Medicines Evaluation Agency regulations; our volatile stock price;
the impact of tariffs on our business, and other risks and uncertainties
detailed in Repligen’s filings with the U.S. Securities and Exchange Commission
(the Commission), including our Annual Report on Form 10-K for the year ended
December 31, 2025 and in subsequently filed reports with the Commission,
including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and
any subsequent filings made with the Commission, which are available at the
Commission’s website at www.sec.gov. Actual results may differ materially from
those Repligen contemplated by these forward-looking statements, which reflect
management’s current views, expectations, and assumptions regarding the future
of our business, future plans and strategies, projections, anticipated events
and trends, the economy and other future conditions, and are based only on
information currently available to us. Repligen cautions you not to place undue
reliance on any forward-looking statements, which speak only as of the date they
are made. Repligen disclaims any obligation to update or revise any such
statements to reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that may affect the
likelihood that actual results will differ from those set forth in the forward-
looking statements.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
[email protected]
4
REPLIGEN CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, amounts in thousands, except share data)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
Current assets:
Cash and cash equivalents $ 726,960 $ 566,021
Marketable securities 136,019 201,607
Accounts receivable, net of
allowances
of $3,273 and $2,767 at September 30, 151,235 158,587
2026, and December 31, 2025,
respectively
Inventories, net 182,205 170,458
Prepaid expenses and other current 45,565 40,712
assets
Total current assets 1,241,984 1,137,385
Property, plant and equipment, net 163,561 186,614
Intangible assets, net 305,291 386,147
Goodwill 1,100,319 1,114,408
Deferred tax assets 716 694
Operating lease right of use assets 112,472 119,538
Other noncurrent assets 2,065 4,913
Total assets $ 2,926,408 $ 2,949,699
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 27,697 $ 30,010
Operating lease liabilities 20,397 21,559
Contingent consideration 2,254 5,049
Accrued liabilities 75,338 79,208
Total current liabilities 125,686 135,826
Convertible Senior Notes due 2028, 555,596 542,213
net
Deferred tax liabilities 19,909 22,496
Noncurrent operating lease 116,248 126,176
liabilities
Noncurrent contingent consideration — 1,304
Other noncurrent liabilities 17,232 15,555
Total liabilities 834,671 843,570
Stockholders' equity:
Preferred stock, $0.01 par value,
5,000,000 shares authorized, no — —
shares
issued or outstanding
Common stock, $0.01 par value;
80,000,000 shares authorized;
56,692,755
shares at September 30, 2026, and 567 563
56,325,429 shares at December 31,
2025,
issued and outstanding
Additional paid-in capital 1,685,620 1,651,849
Accumulated other comprehensive loss -25,607 -2,531
Retained earnings 431,157 456,248
Total stockholders’ equity 2,091,737 2,106,129
Total liabilities and stockholders’ $ 2,926,408 $ 2,949,699
equity
5
REPLIGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, amounts in thousands, except per share data)
Thr… Nine
Mon… Mon…
End… End…
Sep… Sep…
30, 30,
R… 2026 20… 2026 20…
──────────────────────────────────────────────────────────────────────────────
P… $ 20… $ 188… $ 60… $ 540…
R…
a… 44 39 131 111
o…
r…
T… 20… 188… 60… 540…
r…
C…
a…
o…
e…
C…
of 98… 88,… 27… 255…
g…
s…
R…
a… 14… 14,… 43… 40,…
d…
S…
g… 83… 73,… 23… 215…
a…
a…
R…
a…
a… 1,… — 6,… 4,1…
o…
c…
I…
a… 41… — 41… —
i…
c…
C…
in
f…
v… -7… -4,… 1,… -12…
of
c…
c…
T…
c…
a… 23… 171… 60… 503…
o…
e…
(…
i… -2… 16,… 370 37,…
f…
o…
O…
i…
(…
n…
I… 7,… 6,9… 19… 20,…
i…
I… -5… -5,… -1… -16…
e…
A…
of
d… -4… -416 -1… -1,…
i…
c…
L…
on
s… -34 — -1… —
of
b…
O…
i… 1,… -804 883 2,4…
(…
n…
O…
i… 2,… 287 -1… 5,9…
(…
n…
(…
i…
b… -2… 17,… -1… 43,…
i…
t…
I…
t… 11… 2,2… 14… 7,6…
p…
N…
(… $ -3… $ 14,… $ -2… $ 35,…
i…
(…
e…
p…
s…
B… $ -0… $ 0.27 $ -0… $ 0.63
D… $ -0… $ 0.26 $ -0… $ 0.63
W…
a…
c…
s…
o…
B… 56,… 56… 56,… 56…
D… 56,… 56… 56,… 56…
6
REPLIGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, amounts in thousands)
Nine Months Ended
Cash flows from September 30,
operating activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net (loss) income $ -25,091 $ 35,607
Adjustments to
reconcile net (loss)
income to net cash
provided by operating
activities:
Depreciation and 57,948 58,794
amortization
Intangible asset 41,242 —
impairment charges
Amortization of debt
discount and 13,383 12,360
issuance costs
Inventory step-up — 1,069
amortization
Loss on sale of 13,694 —
business
Stock-based 25,690 24,621
compensation
Deferred income taxes, -944 -5,784
net
Change in fair value
of contingent 1,459 -12,087
consideration
Net unrealized foreign
exchange loss -683 -12,443
(gain)
Operating lease right
of use asset 14,189 13,570
amortization
Other adjustments and -1,754 2,532
non-cash items
Changes in operating
assets and
liabilities, excluding
impact of
acquisitions:
Accounts receivable 3,383 -7,302
Inventories -16,070 -5,346
Prepaid expenses and
other current -3,732 -5,494
assets
Other noncurrent 1,916 -1,727
assets
Accounts payable -523 -5,083
Accrued liabilities -2,443 9,629
Operating lease -18,796 -12,096
liabilities
Noncurrent liabilities 1,292 893
Total cash provided by
operating 104,160 91,713
activities
Cash flows from (for)
investing
activities
Acquisitions, net of — -69,954
cash acquired
Divestiture proceeds,
net of cash 3,637 —
divested
Purchases of -200,499 —
marketable securities
Maturities and sales
of marketable 271,073 —
securities
Additions to
capitalized software -1,307 -2,055
costs
Purchases of property,
plant and -14,992 -15,366
equipment
Sale of property, — 42
plant and equipment
Other investing — -2,397
activities
Total cash provided by
(used in) 57,912 -89,730
investing activities
Cash flows from (for)
financing
activities
Proceeds from exercise 15,850 2,142
of stock options
Payment of tax
withholding obligation
on -7,765 -7,994
vesting of restricted
stock
Payment of earnout -5,225 -9,548
consideration
Total cash provided by
(used in) 2,860 -15,400
financing activities
Effect of exchange
rate changes on cash, -1,943 4,809
cash equivalents and
restricted cash
Net increase
(decrease) in cash,
cash 162,989 -8,608
equivalents and
restricted cash
Cash, cash equivalents
and restricted $ 566,021 $ 757,355
cash, beginning of
period
Cash, cash equivalents
and restricted $ 729,010 $ 748,747
cash, end of period
7
RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES
(Unaudited, amounts in thousands, except percentage and earnings per share data)
In all tables below, totals may not add due to rounding
Reconciliation of Total Revenue (GAAP) Growth to Organic Revenue Growth (Non-
GAAP)
Three Nine
Months Months
Ended Ended
September Septemb…
30, 30,
2026 2025 2026 2025
TOTAL
REPORT…
REVENUE 11 % 22 % 13 % 16 %
(GAAP)
GROWTH
Acquis…
and 1 % -2 % 0 % -1 %
divest…
revenue
Curren… 1 % -2 % -1 % -1 %
exchan…
ORGANIC
REVENUE 12 % 18 % 12 % 14 %
GROWTH
(NON-G…
Reconciliation of (Loss) Income from Operations (GAAP) to Adjusted Income from
Operations (Non-GAAP)
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
(LO…
INC…
FROM $ -29,… $ 16,8… $ 370 $ 37,2…
OPE…
(GA…
ADJ…
TO
(LO…
INC…
FROM
OPE…
(GA…
Acq…
int…
and 8,078 4,406 12,8… 14,7…
div…
cos…
Res…
act…
and 1,966 186 6,180 4,357
oth…
cha…
Tra… 3,271 -975 6,349 -3,2…
cos…
Int… 9,561 9,963 28,9… 29,2…
amo…
Int…
ass… 41,2… — 41,2… —
imp…
cha…
Con… -703 -4,1… 1,459 -12,…
con…
Inv…
ste… — 492 — 1,069
cha…
Oth… -581 21 -202 707
ADJ…
INC…
FROM $ 33,2… $ 26,7… $ 97,1… $ 72,0…
OPE…
(NO…
OPE…
(LO…
EBIT -14.1 % 8.9 % 0.1 % 6.9 %
MAR…
(GA…
ADJ…
OPE…
(EB… 15.9 % 14.2 % 16.0 % 13.3 %
MAR…
(NO…
8
Reconciliation of Net (Loss) Income (GAAP) to Adjusted Net Income (Non-GAAP)
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
NET
(LO… $ -38,… $ 14,9… $ -25,… $ 35,6…
INC…
(GA…
ADJ…
TO
NET
(LO…
INC…
(GA…
Acq…
int…
and 8,078 4,406 12,8… 14,7…
div…
cos…
Res…
act…
and 1,966 186 6,180 4,357
oth…
cha…
Tra… 3,271 -975 6,349 -3,2…
cos…
Int… 9,561 9,963 28,9… 29,2…
amo…
Int…
ass… 41,2… — 41,2… —
imp…
cha…
Con… -618 -4,2… 1,446 -15,…
con…
Inv…
ste… — 492 — 1,069
cha…
Non…
int… 4,209 3,907 12,4… 11,4…
exp…
Amo…
of
debt 422 416 1,262 1,243
iss…
cos…
For…
cur…
imp…
of -1,0… — 504 —
cer…
int…
loa…
Loss
on
sale 34 — 13,6… —
of
bus…
Oth… -581 21 -202 707
Tax
eff…
of 1,732 -3,2… -11,… -10,…
non…
cha…
ADJ…
NET $ 29,8… $ 25,8… $ 87,8… $ 69,2…
INC…
(NO…
NET
(LO…
INC… -18.4 % 7.9 % -4.1 % 6.6 %
MAR…
(GA…
ADJ…
NET
INC… 14.3 % 13.7 % 14.4 % 12.8 %
MAR…
(NO…
Reconciliation of Loss Per Share (GAAP) to EPS (Non-GAAP)
Three Nine
Months Months
Ended Ended
September September
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
(LOSS)
EPS $ -0.68 $ 0.26 $ -0.44 $ 0.63
(GAAP) -
DILUTED
ADJUSTM…
TO
(LOSS)
EPS
(GAAP) -
DILUTED:
Acquisi…
integra…
and 0.14 0.08 0.23 0.26
divesti…
costs
Restruc…
activit…
and 0.03 -0.01 0.11 0.02
other
charges…
Transfo… 0.06 0.00 0.11 0.00
costs(2)
Intangi… 0.17 0.18 0.51 0.52
amortiz…
Intangi…
asset 0.72 — 0.73 —
impairm…
charges
Conting… -0.01 -0.07 0.03 -0.27
conside…
Invento…
step-up — 0.01 — 0.02
charges
Non-cash
interest 0.07 0.07 0.22 0.20
expense
Amortiz…
of debt 0.01 0.01 0.02 0.02
issuance
costs
Foreign
currency
impact
of -0.02 — 0.01 —
certain
interco…
loans(3)
Loss on
sale of 0.00 — 0.24 —
business
Other(4) 0.00 0.00 0.00 0.01
Tax
effect
of 0.03 -0.06 -0.21 -0.19
non-GAAP
charges
ADJUSTED
EPS
(NON-GA… $ 0.53 $ 0.46 $ 1.55 $ 1.23
-
DILUTED…
9
Reconciliation of Net (Loss) Income (GAAP) to Adjusted EBITDA (Non-GAAP)
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
NET
(LO… $ -38,… $ 14,9… $ -25,… $ 35,6…
INC…
(GA…
ADJ…
Inv… -7,0… -6,9… -19,… -20,…
inc…
Int… 5,712 5,414 16,9… 16,0…
exp…
Amo…
of
debt 422 416 1,262 1,243
iss…
cos…
Inc…
tax 11,6… 2,201 14,2… 7,663
(be…
pro…
Dep… 9,563 10,1… 29,0… 29,5…
Int… 9,561 9,908 28,9… 29,2…
amo…
(LO…
EBI… $ -8,5… $ 36,0… $ 45,5… $ 98,5…
(NO…
OTH…
ADJ…
Acq…
int…
and 8,078 4,406 12,8… 14,7…
div…
cos…
Res…
act…
and 1,966 186 6,180 4,357
oth…
cha…
Tra… 3,271 -975 6,349 -3,2…
cos…
Int…
ass… 41,2… — 41,2… —
imp…
cha…
Con… -618 -4,2… 1,446 -15,…
con…
Inv…
ste… — 492 — 1,069
cha…
For…
cur…
imp…
of -1,0… — 504 —
cer…
int…
loa…
Loss
on
sale 34 — 13,6… —
of
bus…
Oth… -581 21 -202 707
ADJ…
EBI… $ 43,8… $ 35,9… $ 127,… $ 100,…
(NO…
NET
(LO…
INC… -18.4 % 7.9 % -4.1 % 6.6 %
MAR…
(GA…
ADJ…
EBI… 20.9 % 19.0 % 21.0 % 18.7 %
MAR…
(NO…
FOOTNOTES FOR ALL TABLES ABOVE:
(1) Restructuring activities and other charges includes the costs of severance,
lease impairment and accelerated depreciation among other non-cash charges.
Charges for the three and nine months ended September 30, 2026, consists of
activities to simplify the global manufacturing footprint of the organization
and align its workforce to support long-term company growth.
(2) For the three and nine months ended September 30, 2026, transformation costs
include $3.9 million and $8.8 million, respectively, of expenses for discrete
strategic projects that are designed to deliver long-term growth under our
Transformation Office, partially offset by $0.6 million and $2.5 million,
respectively, for the benefit received from the sale of inventory that had
previously been reserved for as part of past restructuring plans. The three and
nine months ended September 30, 2025, includes a benefit of $1.0 million and
$3.3 million, respectively, from the sale of inventory that had previously been
reserved as part of past restructuring plans.
(3) During the three and nine months ended September 30, 2026, we recorded
foreign currency (gains) and losses on certain intercompany loans of $(1.0)
million and $0.5 million, respectively. This is recorded in other income
(expense), net within the condensed consolidated statements of operations.
(4) Other charges for the three and nine months ended September 30, 2026,
includes other expenses or (benefits) that are non-indicative of our ongoing
performance. The three and nine months ended September 30, 2025 , includes
charges related to one-time events relating to a cybersecurity incident, net of
insurance, and costs associated with the restatement of previously issued
financial statements.
(5) GAAP loss per share—diluted for the three and nine months ended September
30, 2026, excludes 328,882 and 313,150 potentially dilutive shares,
respectively, as their inclusion would have been antidilutive due to the net
loss for each period. Adjusted earnings per share—diluted for the same periods
was calculated using 56,886,642 and 56,757,704 diluted shares, respectively.
10